Publications by authors named "Shifan Lv"
Article Synopsis
- Peritoneal dialysis (PD), specifically automated PD (APD), has potential benefits for patients with end-stage renal disease (ESRD) needing immediate dialysis, though evidence comparing APD to temporary hemodialysis (HD) is limited in China.
- A multicenter randomized controlled trial with 116 ESRD patients showed that APD resulted in significantly fewer dialysis-related complications after one year compared to HD (25.9% vs. 56.9%).
- APD also had lower initial hospitalization costs (27,008.39 CNY) than HD (42,597.54 CNY) but did not show significant differences in catheter survival, peritonitis-free survival, or overall patient survival rates, providing insights
Background: Recent evidence suggests that automated peritoneal dialysis (APD) might be a feasible alternative to hemodialysis (HD) in urgent-start peritoneal dialysis.
Methods: This prospective study enrolled end-stage renal disease (ESRD) patients who had started APD as an urgent-start dialysis modality at a single center. Dialysis-related complications were recorded.
Background: Several studies have reported the feasibility of urgent-start peritoneal dialysis (PD) as an alternative to hemodialysis (HD) using a central venous catheter (CVC). However, the cost-effectiveness of automated peritoneal dialysis (APD) as an urgent-start dialysis modality has not been directly evaluated, especially in China.
Methods: We prospectively enrolled patients with end-stage renal disease (ESRD) who required urgent-start dialysis at a single center from March 2019 to November 2020.